One Fin Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

One Fin Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-300,000	Closed	-$207K	–	32
2020 Q4	$207K	Buy	+300,000	New	+$639K	0.1%	20
2020 Q3	–	Sell	-227,100	Closed	-$813K	–	27
2020 Q2	$813K	Hold	227,100	–	–	0.61%	18
2020 Q1	$863K	Buy	227,100 +25,000	+12%	+$82.4K	0.65%	20
2019 Q4	$608K	Buy	+202,100	New	+$526K	0.33%	21

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

One Fin Capital Management's BMY.RT Position: Q1 2021 in Review

One Fin Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 300,000 shares — an estimated $207K sold.

One Fin Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $863K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

One Fin Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
One Fin Capital Management sold 300,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $207K.
One Fin Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
One Fin Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $863K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on One Fin Capital Management's 13F filing for Q1 2021, filed 17 May 2021.